
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter C - Drugs: General
#### PART 201 - LABELING
##### Subpart B - Labeling Requirements for Prescription Drugs and/or Insulin
###### ยง 201.57 Specific requirements on content and format of labeling for human prescription drug and biological products described in ยง 201.56(b)(1).
####### name of drug

Clinical studies of () did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
